Live
- Gram Sabhas drive to bolster democracy, says tourism minister
- The Young Turk
- The popular, accessible leader
- 488 asst professor posts to be filled in medical colleges
- A passion for public service
- Vignan’s University gets ABET recognition
- Govt asks eligible farmers to contact agricultural officers
- Minister assures development of villages under NDA rule
- PM Modi highlights Mahatma's Gandhi’s message of peace
- A Historic Handshake & Hug: India stands with Ukraine
Completes acquisition of UCB brands
Completes acquisition of UCB brands. Dr Reddy’s Laboratories has completed the acquisition of select portfolio of established brands of Belgian firm UCB in India. “With regard to acquisition of select portfolio of the established products business of UCB in India, Dr Reddy’s Laboratories has concluded the transaction,” the company said in a statement.
.jpg)
Dr Reddy’s Laboratories has completed the acquisition of select portfolio of established brands of Belgian firm UCB in India. “With regard to acquisition of select portfolio of the established products business of UCB in India, Dr Reddy’s Laboratories has concluded the transaction,” the company said in a statement.
On April 1, the drug firm had said that it would acquire select portfolio of established brands of UCB in India, Nepal, Sri Lanka and Maldives for Rs 800 crore. The company had entered into a definitive agreement with UCB which also entails absorbing 350 mployees engaged in the operations of India business.
Dr Reddy’s has said the acquired UCB portfolio would accelerate its presence in the high growth areas of dermatology, respiratory and pediatrics, with market leading brands such as Atarax, Nootropil, Zyrtec, Xyzal and Xyzal M.
